Teriflunomide: Pediatric First Approval
Teriflunomide: Pediatric First Approval
About this item
Full title
Author / Creator
Publisher
Cham: Springer International Publishing
Journal title
Language
English
Formats
Publication information
Publisher
Cham: Springer International Publishing
Subjects
More information
Scope and Contents
Contents
Teriflunomide (Aubagio
®
), which was developed by Sanofi, is an oral immunomodulatory agent targeting the mitochondrial enzyme dihydroorotate dehydrogenase and available to adults to treat relapsing-remitting multiple sclerosis (MS). On 18 June 2021, teriflunomide received its first approval in this indication in pediatric patients aged ≥ 10...
Alternative Titles
Full title
Teriflunomide: Pediatric First Approval
Authors, Artists and Contributors
Author / Creator
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_journals_2595669185
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_journals_2595669185
Other Identifiers
ISSN
1174-5878
E-ISSN
1179-2019
DOI
10.1007/s40272-021-00471-1
